Laser interstitial thermal therapy compared with open resection for treating subependymal giant cell astrocytoma

被引:7
作者
Aum, Diane J. [2 ,5 ]
Reynolds, Rebecca A. [1 ]
Mcevoy, Sean D. [2 ]
Wong, Michael [3 ,4 ]
Roland, Jarod L. [2 ]
Smyth, Matthew D. [1 ]
机构
[1] Johns Hopkins All Childrens Hosp, Div Pediat Neurosurg, St Petersburg, FL USA
[2] Dept Neurol Surg, Washington Univ, St Louis, MO USA
[3] Washington Univ, Sch Med, Dept Neurol, St Louis, MO USA
[4] Washington Univ, Hope Ctr Neurol Disorders, Sch Med, St Louis, MO USA
[5] Washington Univ, St Louis, MO 63130 USA
关键词
tuberous sclerosis; subependymal giant cell astrocytoma; SEGA; laser interstitial thermal therapy; LITT; TUBEROUS SCLEROSIS COMPLEX; DIAGNOSTIC-CRITERIA; TUMORS; MANAGEMENT; EVEROLIMUS; EPILEPSY; IDENTIFICATION; PATHOGENESIS; CHILDREN; GENE;
D O I
10.3171/2023.8.PEDS23370
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE Subependymal giant cell astrocytomas (SEGAs) are WHO grade 1 tumors associated with tuberous sclerosis that classically arise from the ventricular wall near the caudate groove and foramen of Monro. Laser interstitial thermal therapy (LITT) is a minimally invasive surgical technique, which works by heating a stereotactically placed laser fiber to ablative temperatures under MRI thermometry monitoring. In this paper, the authors present LITT as a surgical alternative to open resection of SEGAs. METHODS Twelve patients with SEGAs who underwent 16 procedures between 2007 and 2022 at a single institution were retrospectively reviewed. These patients underwent either open resection or LITT. Clinical data, imaging, recurrence rate, further treatments, and related complications were analyzed. RESULTS Among the 16 procedures, 9 were open resection and 7 were LITT. An external ventricular drain was placed in 66% (6/9) of open procedures and 57.1% (4/7) of LITT cases. A septostomy was performed in 56% (5/9) of open procedures and 29% (2/7) of LITT cases. Complication rates were higher in open cases than in LITT procedures (44% vs 0%, p < 0.05). Complications included hydrocephalus, transient venous ischemia, wound infection, and bone flap migration. The median length of hospital stay was 4 days (IQR 3.3-5.5 days) for open cases and 4 days (IQR 3.0-7.0 days) for LITT procedures. Recurrence or progression occurred after 3 open cases and 2 LITT cases (33% vs 33%, p = 0.803). For the recurrences, 2 open cases underwent stereotactic radiosurgery, 1 open case underwent LITT, and 1 LITT case underwent repeat LITT. Among the LITT cases, only the patients with no decrease in tumor size by 6 months experienced tumor progression afterward. The 2 LITT cases with progression were the only ones with calcification present on preoperative imaging. The median follow-up times for cases assessed for progression were 8.4 years (IQR 3.8-14.4 years) for open resection and 3.9 years (IQR 3.4-5.1 years) for LITT. CONCLUSIONS The small size of this case series limits generalizability or adequate comparison of safety. However, this series adds to the literature supporting LITT as a less invasive surgical alternative to open resection of SEGAs and demonstrates that LITT has similar recurrence and/or progression rates to open resection. Additional studies with more data are necessary for comprehensive comparisons between open resection and LITT for treating SEGA.
引用
收藏
页码:95 / 104
页数:10
相关论文
共 50 条
  • [21] Subependymal giant-cell astrocytoma: A surgical review in the modern era of mTOR inhibitors
    Danassegarane, G.
    Tinois, J.
    Sahler, Y.
    Aouaissia, S.
    Riffaud, L.
    NEUROCHIRURGIE, 2022, 68 (06) : 627 - 636
  • [22] Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin
    Cheng, Sylvia
    Hawkins, Cynthia
    Taylor, Michael D.
    Bartels, Ute
    PEDIATRIC NEUROLOGY, 2015, 53 (03) : 238 - 242
  • [23] Response of Subependymal Giant Cell Astrocytoma With Spinal Cord Metastasis to Everolimus
    Aguilera, Dolly
    Flamini, Robert
    Mazewski, Claire
    Schniederjan, Matthew
    Hayes, Laura
    Boydston, William
    Castellino, Robert C.
    MacDonald, Tobey J.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2014, 36 (07) : E448 - E451
  • [24] Subependymal giant cell astrocytoma with intratumoral hemorrhage Report of 2 cases
    Ogiwara, Hideki
    Morota, Nobuhito
    JOURNAL OF NEUROSURGERY-PEDIATRICS, 2013, 11 (04) : 469 - 472
  • [25] Natural History and Current Treatment Options for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex
    Jowiak, Sergiusz
    Mandera, Marek
    Mlynarski, Wojciech
    SEMINARS IN PEDIATRIC NEUROLOGY, 2015, 22 (04) : 274 - 281
  • [26] Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA)
    Ebrahimi-Fakhari, Daniel
    Franz, David Neal
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (11) : 1329 - 1336
  • [27] Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex
    Jozwiak, Sergiusz
    Stein, Karen
    Kotulska, Katarzyna
    FUTURE ONCOLOGY, 2012, 8 (12) : 1515 - 1523
  • [28] Subependymal giant cell astrocytoma with oncocytic change
    Utsuki, Satoshi
    Oka, Hidehiro
    Kijima, Chihiro
    Yasui, Yoshie
    Fujii, Kiyotaka
    Kawano, Nobuyuki
    Yagishita, Saburo
    BRAIN TUMOR PATHOLOGY, 2011, 28 (01) : 53 - 57
  • [29] GPNMB expression differentiates subependymal giant cell astrocytoma from other mimickers
    Pan, Rui
    Wang, Xiaotong
    Fang, Ru
    Xia, Qiuyuan
    Wang, Xuan
    Zhang, Rusong
    Wei, Xue
    Wu, Nan
    Rao, Qiu
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2025, 75
  • [30] Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus
    Arroyo, Monica S.
    Krueger, Darcy A.
    Broomall, Eileen
    Stevenson, Charles B.
    Franz, David N.
    PEDIATRIC NEUROLOGY, 2017, 72 : 81 - 85